Subtype
Lung Carcinoma
CI-CAN-00001086Explore in graph →
2,130 active trials51 approved drugs598 evidence items
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00001086Explore in graph →
Clinical trials
7,792 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,179)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06951464 | A Study of BL-B01D1 and Almonertinib in Patients With Resectable EGFR+ Stage II-IIIB NSCLC | recruiting | Phase 2 | 40 | Sichuan UniversityOTHER | 1 | Jul 23, 2025 | clinicaltrials |
| NCT07052669 | Hypofractionated Versus Conventional Chemoradiotherapy Followed by Consolidative Immunotherapy in Locally Advanced NSCLC | recruiting | Phase 3 | 311 | Sun Yat-sen UniversityOTHER | 1 | Jul 23, 2025 | clinicaltrials |
| NCT04136535 | Pemetrexed and Carboplatin With or Without Anlotinib Hydrochloride for Osimertinib-resistant Non-squamous NSCLC(PCA) | recruiting | Phase 2 | 105 | Fudan UniversityOTHER | 1 | Jul 22, 2025 | clinicaltrials |
| NCT07008287 | Real-world Study of Taletrectinib for Advanced ROS1+ NSCLC With Brain Metastases | recruiting | — | 100 | Innovent Biologics (Suzhou) Co. Ltd.INDUSTRY | 1 | Jul 22, 2025 | clinicaltrials |
| NCT06709859 | Afatinib Combined With Chemotherapy as Conversion Therapy in Unresectable EGFR Sensitive Mutation-positive Stage III NSCLC | recruiting | Phase 2 | 30 | Shandong Public Health Clinical CenterOTHER_GOV | 1 | Jul 17, 2025 | clinicaltrials |
| NCT07070011 | Small Extracellular Vesicle miRNAs as Predictive Biomarkers for Immunochemotherapy Efficacy in Extensive-stage Small Cell Lung Cancer | recruiting | — | 38 | Shanghai Chest Hospital of Shanghai Jiao Tong UniversityOTHER | 1 | Jul 17, 2025 | clinicaltrials |
| NCT06167460 | Analysis of Circulating Tumor DNA Dynamics to Predict and Monitor Response to TKI in Patients With Advanced NSCLC. | recruiting | — | 50 | Gene SolutionsINDUSTRY | 1 | Jul 16, 2025 | clinicaltrials |
| NCT06457906 | SRS/SRT/Hypo-RT Versus HA-WBRT for No More Than 10 Brain Metastases in SCLC(SHARP) | recruiting | Phase 3 | 340 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Jul 16, 2025 | clinicaltrials |
| NCT06962865 | A Phase Ⅱ Study of RC108 in Combination With Furmonertinib for the First-line Treatment of EGFR-Mutated Combined MET-Positive Unresectable Locally Advanced or Recurrent Metastatic NSCLC | recruiting | Phase 2 | 80 | RemeGen Co., Ltd.INDUSTRY | 1 | Jul 16, 2025 | clinicaltrials |
| NCT06617936 | Tislelizumab Combined With Recombinant Human Endostatin Combined With Chemotherapy for Unresectable Stage III Non-small Cell Lung Cancer. | recruiting | Phase 2 | 36 | Hua ZhangOTHER_GOV | 1 | Jul 15, 2025 | clinicaltrials |
| NCT05486650 | An Observational Clinical Study of Stereotactic Radiotherapy for Advanced Non-Small Cell Lung Cancer With Stable Disease After PD-1 Inhibitor Treatment | recruiting | — | 20 | Xinqiao Hospital of ChongqingOTHER | 1 | Jul 14, 2025 | clinicaltrials |
| NCT06379087 | Radiation Therapy Followed by Tislelizumab and Anlotinib Aeoadjuvant/Adjuvant Therapy for Stage II-IIIA NSCLC | recruiting | Phase 2 | 20 | Ji YonglingOTHER | 1 | Jul 10, 2025 | clinicaltrials |
| NCT05086692 | A Beta-only IL-2 ImmunoTherapY Study(ABILITY-1) | recruiting | Phase 1 / Phase 2 | 115 | Medicenna Therapeutics, Inc.INDUSTRY | 7 | Jul 9, 2025 | clinicaltrials |
| NCT06773507 | Phase I Study of BC008-1A Injection in Patients With Advanced Solid Tumors | recruiting | Phase 1 | 80 | Sichuan Luzhou Buchang Biopharmaceutical Co., Ltd.INDUSTRY | 1 | Jul 9, 2025 | clinicaltrials |
| NCT07037680 | Radiotherapy Plus Anlotinib in LA-NSCLC Intolerable to cCRT | recruiting | Phase 2 | 44 | JIANYANG WANGOTHER | 1 | Jul 9, 2025 | clinicaltrials |
| NCT07057102 | Multiple Omics Sequencing Technologies in Predicting the Efficacy and Monitoring the Recurrence of Non-Small Cell Lung Cancer | recruiting | — | 40 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Jul 9, 2025 | clinicaltrials |
| NCT07050043 | Low Dose Nivolumab With Chemotherapy vs Standard Chemotherapy as First-Line Treatment in Advanced or Metastatic NSCLC(LEDANG) | recruiting | Phase 3 | 123 | Dr Arvindran A/L AlagaOTHER_GOV | 1 | Jul 3, 2025 | clinicaltrials |
| NCT03093688 | Clinical Safty and Efficacy Study of Infusion of iNKT Cells and CD8+T Cells in Patients With Advanced Solid Tumor | recruiting | Phase 1 / Phase 2 | 40 | Shanghai Public Health Clinical CenterOTHER_GOV | 1 | Jul 2, 2025 | clinicaltrials |
| NCT06946927 | A Phase Ib Study of JMKX001899 in Combination With Other Therapies in Advanced NSCLC Harboring KRAS G12C Mutation | recruiting | Phase 1 | 72 | JemincareINDUSTRY | 1 | Jul 1, 2025 | clinicaltrials |
| NCT05989542 | A Confirmatory Clinical Study in NSCLC Patients With MET Exon 14 Mutation (KUNPENG-2)(KUNPENG-2) | recruiting | Phase 3 | 136 | Beijing Pearl Biotechnology Limited Liability CompanyINDUSTRY | 1 | Jun 29, 2025 | clinicaltrials |
| NCT03175224 | APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors(SPARTA) | recruiting | Phase 2 | 497 | Apollomics Inc.INDUSTRY | 11 | Jun 27, 2025 | clinicaltrials |
| NCT06436625 | Outpatient Pulmonary Rehabilitation in Non-small-cell Lung Cancer Receiving Immunotherapy(OPAL) | recruiting | N/A | 70 | Karl Landsteiner Institute for Lung Research and Pneumological OncologyOTHER | 1 | Jun 26, 2025 | clinicaltrials |
| NCT07039994 | Early Palliative Care in Patients With Advanced Lung Cancer Using an e-Health Ecosystem(AIRPAL) | recruiting | N/A | 200 | Jesús GonzálezOTHER_GOV | 1 | Jun 26, 2025 | clinicaltrials |
| NCT05623319 | Pembrolizumab and Olaparib Treatment of Extensive Small Cell Lung Cancer (ES-SCLC)(THOR) | recruiting | Phase 2 | 60 | Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCSOTHER | 1 | Jun 24, 2025 | clinicaltrials |
| NCT06980272 | SSGJ-707 in Advanced Non-Small Cell Lung Cancer | recruiting | Phase 3 | 420 | Shenyang Sunshine Pharmaceutical Co., LTD.INDUSTRY | 1 | Jun 24, 2025 | clinicaltrials |
| NCT07034326 | Electroacupuncture Combined With Immune Checkpoint Inhibitors as Adjuvant Therapy After Surgery for Early-stage Non-small Cell Lung Cancer | recruiting | Phase 2 / Phase 3 | 405 | Kong FanmingOTHER | 1 | Jun 24, 2025 | clinicaltrials |
| NCT07034391 | A Study Evaluating the Efficacy of PD-1 Inhibitor Combined With Denosumab and Chemotherapy in Locally Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer Patients With Driver Gene-Negative Status | recruiting | Phase 2 | 40 | China Medical University, ChinaOTHER | 1 | Jun 24, 2025 | clinicaltrials |
| NCT06276283 | DZD9008 In Combination With Bevacizumab in Locally Advanced or Metastatic NSCLC Patients With EGFR Mutation (WU-KONG29) | recruiting | Phase 2 | 60 | Dizal PharmaceuticalsINDUSTRY | 1 | Jun 19, 2025 | clinicaltrials |
| NCT07003490 | Radical Resection With Contralateral Lymph Node Dissection for Clinical N3 NSCLC | recruiting | N/A | 30 | Shanghai General Hospital, Shanghai Jiao Tong University School of MedicineOTHER | 1 | Jun 19, 2025 | clinicaltrials |
| NCT06954246 | A Study of MHB088C Injection Versus Treatment of Physician's Choice in Subjects With Relapsed Small Cell Lung Cancer | recruiting | Phase 3 | 450 | Qilu Pharmaceutical Co., Ltd.INDUSTRY | 1 | Jun 18, 2025 | clinicaltrials |
| NCT07026669 | A Multi-omics Sequencing-based Model for Predicting Efficacy and Dynamic Monitoring of Treatment in Small Cell Lung Cancer | recruiting | — | 40 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Jun 18, 2025 | clinicaltrials |
| NCT06205927 | Randomized Study of Carbon Ion Boost in Hypoxic Lesions for Locally Advanced Non-small Cell Lung Cancer | recruiting | Phase 2 | 77 | Jian ChenOTHER | 1 | Jun 17, 2025 | clinicaltrials |
| NCT07008742 | Feasibility Study of Tissue and Blood Collection in Oncogene-addicted and Neoadjuvantly Treated Non Small Cell Lung Cancer(FeStival) | recruiting | — | 100 | Royal Marsden NHS Foundation TrustOTHER | 1 | Jun 15, 2025 | clinicaltrials |
| NCT05613452 | Carbon Ion Therapy for Peripheral Non-small Cell Lung Cancer | recruiting | Phase 2 | 43 | Shanghai Proton and Heavy Ion CenterOTHER | 1 | Jun 13, 2025 | clinicaltrials |
| NCT06311981 | Carbon Ion Radiotherapy for Locally Advanced Lung Cancer in Elderly Patients | recruiting | Phase 2 | 29 | Jian ChenOTHER | 1 | Jun 13, 2025 | clinicaltrials |
| NCT04952480 | Dose-escalated Adaptive Radiotherapy of Thoracic Disease for Small Cell Lung Cancer(DARTS) | recruiting | Phase 2 | 31 | AHS Cancer Control AlbertaOTHER | 1 | Jun 12, 2025 | clinicaltrials |
| NCT05765877 | Neoadjuvant WX-0593 in Resectable ALK-positive or ROS1-positive Non-small Cell Lung Cancer | recruiting | Phase 2 | 26 | Pingping SongOTHER | 1 | Jun 12, 2025 | clinicaltrials |
| NCT06418412 | A Pan-Asian Clinical Database of EGFR Exon 20 Insertion Mutated NSCLC | recruiting | — | 600 | National Cancer Centre, SingaporeOTHER | 3 | Jun 12, 2025 | clinicaltrials |
| NCT07016126 | D-BACE in Combination With Chemotherapy and Carelizumab for Resectable II-IIIA or Potentially Resectable T3-4N2 Stage IIIB NSCLC | recruiting | Phase 3 | 70 | Guangdong Provincial People's HospitalOTHER | 1 | Jun 11, 2025 | clinicaltrials |
| NCT06754644 | A Study to Evaluate Efficacy, and Safety of QL2107 Plus Chemo and Compare With Keytruda in Participants With IV nqNSCLC | recruiting | Phase 3 | 808 | Qilu Pharmaceutical Co., Ltd.INDUSTRY | 1 | Jun 10, 2025 | clinicaltrials |
| NCT06929936 | Trilaciclib in Combination With Docetaxel for Second-Line and Beyond Treatment of Locally Advanced or Metastatic NSCLC(PROTECT-1) | recruiting | Phase 2 | 33 | The First Affiliated Hospital of Xiamen UniversityOTHER | 1 | Jun 8, 2025 | clinicaltrials |
| NCT06596915 | Safety and Efficacy of BA1302 in Patients With Advanced Solid Tumors | recruiting | Phase 1 | 167 | Shandong Boan Biotechnology Co., LtdINDUSTRY | 1 | Jun 6, 2025 | clinicaltrials |
| NCT06969612 | A Study on the Efficacy and Safety of Golidocitinib Combined With Tislelizumab and Chemotherapy as First-line Treatment for Advanced NSCLC | recruiting | Phase 1 | 21 | Peking University Cancer Hospital & InstituteOTHER | 1 | Jun 6, 2025 | clinicaltrials |
| NCT07008716 | Omitting CTV for Primary Tumor in LS-SCLC | recruiting | Phase 3 | 852 | Sun Yat-sen UniversityOTHER | 1 | Jun 6, 2025 | clinicaltrials |
| NCT06902350 | Safety, Pharmacokinetics and Preliminary Efficacy of CS231295 in Advanced Solid Tumors | recruiting | Phase 1 | 102 | Chipscreen Biosciences, Ltd.INDUSTRY | 1 | May 25, 2025 | clinicaltrials |
| NCT06977074 | PROPHET Study: ctDNA-Guided Personalized Induction Immunochemotherapy for NSCLC(PROPHET) | recruiting | Phase 2 | 83 | Sun Yat-sen UniversityOTHER | 1 | May 23, 2025 | clinicaltrials |
| NCT04977791 | Analysis of Drug Resistance in Immune Checkpoint Inhibitors of Non-small Cell Lung Cancer | recruiting | — | 250 | Shanghai Chest HospitalOTHER | 1 | May 22, 2025 | clinicaltrials |
| NCT05701787 | Molecular Landscape Analysis and Clinical Implications for NSCLC Patients With Rare Mutations | recruiting | — | 500 | Shanghai Chest HospitalOTHER | 1 | May 22, 2025 | clinicaltrials |
| NCT06343064 | Vebreltinib Plus PLB1004 in EGFR-mutated, Advanced NSCLC With MET Amplification or MET Overexpression Following EGFR-TKI(KYLIN-1) | recruiting | Phase 1 / Phase 2 | 156 | Avistone Biotechnology Co., Ltd.INDUSTRY | 1 | May 21, 2025 | clinicaltrials |
| NCT06574347 | Vebreltinib Plus PLB1004 as the First-line Therapy for Patients With EGFRm+/MET+ Locally Advanced or Metastatic NSCLC.(KYLIN-2) | recruiting | Phase 2 | 120 | Avistone Biotechnology Co., Ltd.INDUSTRY | 1 | May 21, 2025 | clinicaltrials |
Data updated 23 days agoSource updated Jul 23, 2025source: clinicaltrials